GHR Foundation

Established in 1965, GHR Foundation is a U.S.-based non-profit organization dedicated to fostering transformational changes in education, health, and global development. It aims to promote equity, dignity, and care worldwide through its support for initiatives focused on preventing Alzheimer's Disease and related dementias, cultivating an inclusive global Catholic Church, and enhancing financial empowerment and educational excellence in Minneapolis and St. Paul.

Jason Matz

Chief Investment Officer

7 past transactions

C2N Diagnostics

Grant in 2024
C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.

Horizon Next

Grant in 2023
Nowadays AI, Robots and automation are trend, but very soon autonomous devices, car and other machines will be everywhere at our daily life. From our over the horizon vision, "Horizon Next" team is bringing innovation to life, aiming equal and wealth life for humans.

C2N Diagnostics

Venture Round in 2023
C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.

Braille Teach

Grant in 2022
Braille Teach is a device with audio feedback to help blind and visually impaired people learn the Braille alphabet.

Horizon Next

Grant in 2022
Nowadays AI, Robots and automation are trend, but very soon autonomous devices, car and other machines will be everywhere at our daily life. From our over the horizon vision, "Horizon Next" team is bringing innovation to life, aiming equal and wealth life for humans.

C2N Diagnostics

Grant in 2020
C2N Diagnostics, LLC is a privately held company focused on the development of protein diagnostics and therapeutics targeting progressive neurodegeneration, particularly Alzheimer's disease. Founded in 2007 by Drs. David Holtzman and Randall Bateman from Washington University School of Medicine, along with LifeTech Research, the company operates from the Center for Emerging Technologies in St. Louis. C2N Diagnostics specializes in mass spectrometry-based techniques that allow for the precise identification, quantification, and monitoring of proteins and biomolecules associated with neurological disorders. By providing accurate and sensitive diagnostics, the company aims to enhance the detection and characterization of neurocognitive disorders, ultimately supporting improved patient care and treatment strategies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.